Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(01): 34-38
DOI: 10.4103/ijmpo.ijmpo_115_19
Original Article

Tumor-Infiltrating Lymphocytes in Wilms Tumor

Devendra Kumar Yadav
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
,
Vishesh Jain
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
,
Amit Kumar Dinda
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Sandeep Agarwala
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Purpose: T-lymphocytes-infiltrating tumors (TILs) are white blood cells (CD3+) found within the tumor and are thought to indicate a T-cell-mediated specific immune response. The purpose was to evaluate the presence and the subtypes of TILs in Wilms tumor (WT) specimens. Materials and Methods: A prospective study was conducted, and consecutive cases of WT registered and treated at our center were included in the study. The resected tumor was processed by taking multiple sections from the tumor and the peritumoral area. The sections were then processed for evaluating TILs and their subtypes (CD4 + and CD8+). TILs were assessed as a percentage of the total mononuclear cell infiltration in both these areas in all specimens. Results: Twenty-four consecutive specimens of WT were studied. The mean TILs (CD3+) counts was significantly higher (P = 0.001) in the peritumoral area (22.64 ± 1.42; range 20.2%–25%) as compared to the tumor (21.08 ± 2.42; range 14.6%–23.1%). The mean T-Helper (CD4+) counts was also significantly higher (P < 0.001) in the peritumoral area (13.04 ± 1.79; range 10.5%–16.5%) than in the tumor (7.30 ± 1.81; range 4.2%–10.1%). The mean cytolytic T-lymphocytes (CTLs-CD8+) counts in peritumoral area were 6.64 ± 1.09 (range 4.2%–9.2%), while in the tumor, it was 11.96 ± 3.09 (range 3.6%–16.4%). Two patients died on follow-up due to recurrence. These patients showed a markedly lower CD8+ cell count and higher CD4+/CD8+ ratio in the tumor. Conclusion: T-cells infiltration takes place in WT, and most of the patients demonstrate a higher concentration of CTL (CD8+) in the tumor as compared to the peritumoral area.

Keywords

Immunosurveillance - tumor-infiltrating lymphocytes - Wilms tumor


Publication History

Received: 12 May 2019

Accepted: 10 November 2019

Article published online:
23 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kreider JW, Bartlett GL, Butkiewicz BL. Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. Cancer Metastasis Rev 1984; 3: 53-74
    CrossrefPubMedGoogle Scholar
  • 2 Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-81
    CrossrefPubMedGoogle Scholar
  • 3 Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. PLoS One 2016; 11: e0152500
    CrossrefPubMedGoogle Scholar
  • 4 Yu X, Zhang Z, Wang Z, Wu P, Qiu F, Huang J. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. Clin Transl Oncol 2016; 18: 497-506
    CrossrefPubMedGoogle Scholar
  • 5 Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 2017; 8: 15621-31
    CrossrefPubMedGoogle Scholar
  • 6 Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F. et al. Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11: 19
    CrossrefPubMedGoogle Scholar
  • 7 Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T. et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A systematic review and meta-analysis. Sci Rep 2017; 7: 7525
    CrossrefPubMedGoogle Scholar
  • 8 Liu H, Zhang T, Ye J, Li H, Huang J, Li X. et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012; 61: 1849-56
    CrossrefPubMedGoogle Scholar
  • 9 Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J. et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: A meta-analysis. Cell Physiol Biochem 2015; 37: 1560-71
    CrossrefPubMedGoogle Scholar
  • 10 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L. et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015; 6: 24990-5002
    CrossrefPubMedGoogle Scholar
  • 11 Lee N, Zakka LR, Mihm Jr. MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 2016; 48: 177-87
    CrossrefPubMedGoogle Scholar
  • 12 Kim KJ, Lee KS, Cho HJ, Kim YH, Yang HK, Kim WH. et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol 2014; 45: 285-93
    CrossrefPubMedGoogle Scholar
  • 13 Mina M, Boldrini R, Citti A, Romania P, D’Alicandro V, De Ioris M. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 2015; 4: e1019981
    CrossrefPubMedGoogle Scholar
  • 14 Mochizuki K, Kawana S, Yamada S, Muramatsu M, Sano H, Kobayashi S. et al. Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy. Pediatr Hematol Oncol 2019; 36: 17-27
    CrossrefPubMedGoogle Scholar
  • 15 Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9
    CrossrefPubMedGoogle Scholar
  • 16 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48
    CrossrefPubMedGoogle Scholar
  • 17 Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L. et al. Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. Expert Rev Anticancer Ther 2015; 15: 689-702
    CrossrefPubMedGoogle Scholar
  • 18 Vesely MD, Schreiber RD. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284: 1-5
    CrossrefPubMedGoogle Scholar
  • 19 Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2016; 5: 2567-78
    CrossrefPubMedGoogle Scholar
  • 20 Nagai K, Yamada A, Eguchi H, Kato H, Itoh K. HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilms’ tumor. Pediatr Res 1997; 42: 122-7
    CrossrefPubMedGoogle Scholar
  • 21 Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F. et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-43
    CrossrefPubMedGoogle Scholar